Episode Details

Back to Episodes
Should We Be Concerned About Resistance and Development of New Variants With COVID-19 Antiviral Therapy?

Should We Be Concerned About Resistance and Development of New Variants With COVID-19 Antiviral Therapy?

Episode 243 Published 3 years, 2 months ago
Description

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 treatments and the possibility for antiviral resistance, including:

  • Treatment resistance mechanisms
  • COVID-19 testing
  • COVID-19 treatments, including antivirals and monoclonal antibodies

Presenters:
Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director
COVID Center of Excellence Satellite-Ansonia 
Mount Sinai Health 
New York, New York

Rasika Karnik, MS, MD
Assistant Professor
Division of Primary Care
Department of Internal Medicine
University of Chicago
Medical Director
Post-COVID Recovery Clinic
Chicago, Illinois

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Joseph Torrisi, PharmD, BCIDP
Clinical Pharmacy Specialist
Infectious Diseases 
Pharmacy
Grady Health System
Atlanta, Georgia

Link to slides: 
https://bit.ly/3hXMgId

Link to full program: 
https://bit.ly/3G271KL


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us